VEGFA and renal cell adenocarcinoma: For example, in Javelin Renal 101,60 ImMotion150,61 and ImMotion 15162 RCC cohorts, patients receiving anti-PD-L1 treatment were also treated with VEGF inhibitors or anti-VEGF treatments concurrently.